Harmony BioSciences' Wakix Franchise, Pipeline Offer Multiple Value Drivers, Oppenheimer Says
MT newswire2026/10/08 15:4511:45 AM EDT, 10/08/2026 (MT Newswires) -- Harmony BioSciences (HRMY) has several underappreciated value drivers supporting its long-term growth outlook, including its Wakix franchise, pitolisant lifecycle initiatives and BP-205 program, Oppenheimer said in a note Wednesday. Patient count for narcolepsy treatment Wakix rose by 450 in Q2 to roughly 8,950, keeping the company on track for more than $1 billion in 2026 revenue, supported by broad physician awareness, more than 80% covered lives and improved patient onboarding processes, according to the note. The brokerage said Harmony's IP strategy could support Wakix exclusivity through March 2030, while the pitolisant GR and HD programs may extend the franchise beyond 2030, with utility patents potentially offering protection into the 2040s. Oppenheimer also highlighted BP-205, an orexin-2 receptor agonist under clinical development, which provides a longer-term opportunity given its differentiated potency and potential applications across hypersomnia and multiple CNS indications. Harmony's more than $900 million cash balance supports pipeline development and potential business development deals, the brokerage said. Oppenheimer has an outperform rating on the stock, with a price target of $70. Harmony BioSciences shares were down 1.1% in Thursday trading. Price: 38.91, Change: -0.43, Percent Change: -1.09
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.
Dental treatment company vVardis has announced the terms for its $214 million US IPO.
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss
Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.
CoreWeave (CRWV.US) Faces Key Earnings Test: AI Cloud Debt Concerns Intensify as "Burning Cash for Growth" Model Faces Scrutiny
CoreWeave will release its third-quarter financial report. Whether it can demonstrate that its rapid revenue growth is sufficient to cover the rising financing costs and construction expenditures will directly determine the direction of market confidence.
Crypto prices
More
